Wealthfront Advisers LLC Sells 89,569 Shares of Pfizer Inc. $PFE

Wealthfront Advisers LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 12.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 619,451 shares of the biopharmaceutical company’s stock after selling 89,569 shares during the quarter. Wealthfront Advisers LLC’s holdings in Pfizer were worth $15,015,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in PFE. Ingalls & Snyder LLC boosted its holdings in Pfizer by 7.4% in the second quarter. Ingalls & Snyder LLC now owns 755,313 shares of the biopharmaceutical company’s stock worth $18,309,000 after acquiring an additional 51,993 shares in the last quarter. Burke & Herbert Bank & Trust Co. boosted its stake in Pfizer by 3.6% in the 2nd quarter. Burke & Herbert Bank & Trust Co. now owns 79,749 shares of the biopharmaceutical company’s stock worth $1,933,000 after purchasing an additional 2,737 shares in the last quarter. CVA Family Office LLC grew its position in Pfizer by 141.6% during the 2nd quarter. CVA Family Office LLC now owns 12,502 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 7,327 shares during the last quarter. AG2R LA Mondiale Gestion D Actifs increased its stake in Pfizer by 1.9% during the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 214,608 shares of the biopharmaceutical company’s stock valued at $5,202,000 after purchasing an additional 4,078 shares in the last quarter. Finally, City State Bank raised its holdings in Pfizer by 24.8% in the second quarter. City State Bank now owns 28,701 shares of the biopharmaceutical company’s stock worth $696,000 after buying an additional 5,700 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.5%

Pfizer stock opened at $24.79 on Monday. The stock has a market cap of $140.92 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The stock has a fifty day moving average of $24.87 and a 200 day moving average of $24.20.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Saturday. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.